{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:48:00Z","timestamp":1779886080492,"version":"3.53.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,3,8]],"date-time":"2016-03-08T00:00:00Z","timestamp":1457395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.tranon.2016.08.001","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T00:31:45Z","timestamp":1480638705000},"page":"600-605","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer"],"prefix":"10.1016","volume":"9","author":[{"given":"Sara","family":"Campora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Campazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Zanardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Puntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Piccininno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnoldo","family":"Piccardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Shoushtari Zadeh Naseri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Defferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Provinciali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Petrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ennio","family":"Biscaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Carlo","family":"Antonucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Clavarezza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Gennari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Gozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"DeCensi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2016.08.001_bb0005","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"De Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tranon.2016.08.001_bb0010","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.tranon.2016.08.001_bb0015","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.tranon.2016.08.001_bb0020","doi-asserted-by":"crossref","first-page":"6650","DOI":"10.1158\/1078-0432.CCR-13-2134","article-title":"Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S Food and Drug Administration drug approval summary","volume":"19","author":"Kluez","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.tranon.2016.08.001_bb0025","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1158\/0008-5472.CAN-08-4531","article-title":"Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven","volume":"69","author":"Attard","year":"2009","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.tranon.2016.08.001_bb0030","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1210\/jc.2011-2189","article-title":"Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer","volume":"97","author":"Attard","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.tranon.2016.08.001_bb0035","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/0022-4731(88)90295-6","article-title":"Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture","volume":"31","author":"Luthy","year":"1988","journal-title":"J Steroid Biochem"},{"key":"10.1016\/j.tranon.2016.08.001_bb0040","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.tranon.2016.08.001_bb0045","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1161\/01.CIR.103.3.369","article-title":"Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes","volume":"103","author":"Sato","year":"2001","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.tranon.2016.08.001_bb0050","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00392-012-0530-5","article-title":"Prognostic value of NT-pro-BNP and hs-CRP for risk stratification in primary care: results from the population-based DETECT study","volume":"102","author":"Leistner","year":"2013","journal-title":"Clin Res Cardiol"},{"issue":"4","key":"10.1016\/j.tranon.2016.08.001_bb0055","doi-asserted-by":"crossref","first-page":"380","DOI":"10.5414\/CNP71380","article-title":"NT-pro-BNP is an independent predictor of mortality in patients with end-stage renal disease","volume":"71","author":"Svensson","year":"2009","journal-title":"Clin Nephrol"},{"issue":"20","key":"10.1016\/j.tranon.2016.08.001_bb0060","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.2169\/internalmedicine.51.8027","article-title":"The prognostic value of combined NT-pro-BNP levels and NIHSS scores in patients with acute ischemic stroke","volume":"51","author":"Chen","year":"2012","journal-title":"Intern Med"},{"key":"10.1016\/j.tranon.2016.08.001_bb0065","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/eurjhf\/hfn015","article-title":"Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results","volume":"11","author":"Boccanelli","year":"2009","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.tranon.2016.08.001_bb0070","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.numecd.2010.02.012","article-title":"Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study","volume":"21","author":"De Simone","year":"2011","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.tranon.2016.08.001_bb0080","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"EJC"},{"issue":"13","key":"10.1016\/j.tranon.2016.08.001_bb0085","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [18F]uorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations","volume":"35","author":"Young","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.tranon.2016.08.001_bb0095","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S1470-2045(14)70417-6","article-title":"Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial","volume":"15","author":"CN","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tranon.2016.08.001_bb0100","first-page":"3797","article-title":"Mutation of cytochrome P-45017 alpha gene (CYP17) in a Japanese patient previously reported as having glucocorticoid-responsive hyperaldosteronism: with a review of Japanese patients with mutations of CYP17","volume":"81","author":"Miura","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.tranon.2016.08.001_bb0105","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1056\/NEJMc1107198","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"365","author":"Berruti","year":"2011","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.tranon.2016.08.001_bb0110","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1139\/o79-131","article-title":"Interaction of spironolactone with rat skin androgen receptor","volume":"57","author":"Boisselle","year":"1979","journal-title":"Can J Biochem"},{"key":"10.1016\/j.tranon.2016.08.001_bb0115","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3310\/hta14240","article-title":"A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure","volume":"14","author":"McKenna","year":"2010","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.tranon.2016.08.001_bb0120","first-page":"21","article-title":"Safety of abiraterone acetate in castration-resistant prostate cancer patients with concomitant cardiovascular risk factors","author":"Procopio","year":"2013","journal-title":"Am J Clin Oncol"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523316300365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523316300365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T14:32:32Z","timestamp":1761834752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523316300365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S1936523316300365"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2016.08.001","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2016.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Inc. on behalf of SOCIETY.","name":"copyright","label":"Copyright"}]}}